Back to first-pass browser

First-pass extracted concept

HER2-, GD2-, and B7-H3-directed CAR T cells

Candidate: concept label1 source documents4 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

B7-H3 CAR T cells, CAR T cells, GD2 CAR T cells, HER2 CAR T cells

Extracted Explainers

What the tool is doing

The abstract describes CAR T cells targeting HER2, GD2, and B7-H3 as recent T cell-based strategies for osteosarcoma.

Source 1DOIPubMed

Resources required

These approaches require a CAR T-cell platform and a target antigen such as HER2, GD2, or B7-H3.

Source 1DOIPubMed

What problem it solves

They aim to direct T cells against osteosarcoma-associated surface antigens.

Source 1DOIPubMed

What it does not solve

The abstract states that clinical translation remains limited and that trafficking, suppressive microenvironments, and antigen heterogeneity restrict efficacy.

Source 1DOIPubMed

Alternatives

The abstract contrasts CAR T cells with MHC-independent γδ T cells and checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4.

Source 1DOIPubMed

Evidence Snippets

chimeric antigen receptor (CAR) T cells directed against antigens such as HER2, GD2, and B7-H3
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1barrier mechanismsupports2026Source 1DOIPubMed

An immunosuppressive tumor microenvironment, functional T cell exhaustion, and pronounced antigenic heterogeneity are major reasons for limited immunotherapy efficacy in osteosarcoma.

Claim 2efficacy limitationsupports2026Source 1DOIPubMed

Immunotherapy efficacy in osteosarcoma has been modest.

Claim 3preclinical vs translationsupports2026Source 1DOIPubMed

Recent T cell-based strategies in osteosarcoma, including γδ T cells, checkpoint inhibitors, and CAR T cells, have shown encouraging preclinical activity but limited clinical translation.

Claim 4resistance mechanismsupports2026Source 1DOIPubMed

Impaired antigen presentation, suppressive immune cell populations, and inadequate T cell trafficking collectively restrict therapeutic efficacy in osteosarcoma T cell immunotherapy.